Αρχική World News Undetectable MRD and Extended PFS More Common with MRD-guided Ibrutinib-Venetoclax than with... World News Undetectable MRD and Extended PFS More Common with MRD-guided Ibrutinib-Venetoclax than with Ibrutinib Alone or FCR Regimen Among Patients with CLL Από Ogkologos - 13 Οκτωβρίου, 2025 428 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FLAIR study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Corgi Named Dolly Didn’t Win At Westminster, But Is A Champion... 12 Φεβρουαρίου, 2020 First Mature Estimation of Median OS for Selpercatinib in Patients with... 12 Μαρτίου, 2025 Consistent Efficacy Benefit with Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Patients... 30 Απριλίου, 2024 ESMO Welcomes the WHO Global Status Report on Cancer with Key... 15 Ιουλίου, 2026 Φόρτωση περισσοτέρων HOT NEWS Teacher Reads To Students One Day After Having Brain Surgery ESMO Urges EU Policymakers to Protect the Wellbeing of the Oncology... Rate of Suicides Related to Cancer Is Declining No OS Benefit for Active Maintenance Treatment with Olaparib Relative to...